BCR and acute lymphoblastic leukemia: The fact that BCR–ABL1 has been found mutated at relapse also raises the important question how aggressively patients with Ph+ ALL who receive TKIs on a backbone of standard chemotherapy should be screened for the emergence of TKD mutations.